Hayat Pharmaceutical Industries Co. PLC Stock

Equities

HPIC

JO4121011012

Pharmaceuticals

End-of-day quote Amman S.E. 18:00:00 2024-04-23 EDT 5-day change 1st Jan Change
2.55 JOD +0.79% Intraday chart for Hayat Pharmaceutical Industries Co. PLC 0.00% +6.25%

Financials

Sales 2022 17.11M 24.16M 33.05M Sales 2023 15.81M 22.32M 30.54M Capitalization 22.8M 32.2M 44.05M
Net income 2022 3M 4.24M 5.8M Net income 2023 2M 2.82M 3.86M EV / Sales 2022 1.32 x
Net cash position 2022 5.44M 7.68M 10.51M Net cash position 2023 5.31M 7.5M 10.27M EV / Sales 2023 1.11 x
P/E ratio 2022
7.94 x
P/E ratio 2023
9.8 x
Employees 236
Yield 2022
8.47%
Yield 2023
6.88%
Free-Float 14.81%
More Fundamentals * Assessed data
Dynamic Chart
Hayat Pharmaceutical Industries Co. PLC Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Hayat Pharmaceutical Industries Co. PLC Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Hayat Pharmaceutical Industries Co. PLC Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Hayat Pharmaceutical Industries Co. PLC Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Hayat Pharmaceutical Industries Co. PLC Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Hayat Pharmaceutical Industries Co. PLC Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Hayat Pharmaceutical Industries Co. PLC Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Hayat Pharmaceutical Industries Co. PLC Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Hayat Pharmaceutical Industries Co. plc Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Hayat Pharmaceutical Industries Co. plc Reports Earnings Results for the Third Quarter Ended September 30, 2020 CI
Hayat Pharmaceutical Industries Co. plc Announces Earnings Results for the Second Quarter Ended June 30, 2020 CI
Hayat Pharmaceutical Industries Co. plc Reports Earnings Results for the First Quarter Ended March 31, 2020 CI
Hayat Pharmaceutical Industries Co. plc Reports Earnings Results for the Second Quarter Ended June 30, 2019 CI
Hayat Pharmaceutical Industries Co. plc Reports Earnings Results for the First Quarter Ended March 31, 2019 CI
Hayat Pharmaceutical Industries Co. Reports Earnings Results for the Full Year Ended December 31, 2018 CI
More news
1 day+0.79%
Current month+2.00%
1 month+2.00%
3 months+5.37%
6 months+4.08%
Current year+6.25%
More quotes
1 week
2.53
Extreme 2.53
2.57
1 month
2.50
Extreme 2.5
2.59
Current year
2.40
Extreme 2.4
2.59
1 year
2.40
Extreme 2.4
3.43
3 years
2.40
Extreme 2.4
4.33
5 years
1.72
Extreme 1.72
4.33
10 years
1.40
Extreme 1.4
4.33
More quotes
Managers TitleAgeSince
Chief Executive Officer 65 02-02-16
Chief Tech/Sci/R&D Officer 62 14-06-07
Chief Administrative Officer 71 01-04-07
Members of the board TitleAgeSince
Chief Executive Officer 65 02-02-16
Director/Board Member - 94-04-02
Director/Board Member - -
More insiders
Date Price Change Volume
24-04-24 2.55 +0.79% 81
24-04-23 2.53 -1.17% 893
24-04-21 2.56 +0.39% 1,307

End-of-day quote Amman S.E., April 23, 2024

More quotes
Hayat Pharmaceutical Industries Company PSC is a Jordan-based company engaged in the pharmaceutical sector. The Company specializes in the manufacture of different forms of human pharmaceuticals, veterinary medicines, medical plasters, medical gauze and medical braces, in addition to the production of skin care and beauty supplies and surgical suture. The Company’s manufacturing facility is spread over an approximately 8,000 square meter area on the outskirts of the capital city Amman. The Company’s production areas are divided into the following: Solid production area, which covers tablets, capsules, dry suspension, suppositories, syrups and solutions, cream and ointments, and Semi-solid and Liquid production area, which includes creams, ointments, gels and emulsions, suppositories line, syrups line and shampoo line. The Company’s products include Anti-microbials, Gynecological, Dermatological, Gastrointestinal, Antihypertensives and Vasoactive, Neurological, and Respiratory products.
More about the company